First edition of CaixaImpulse
A few months ago, in a post on new funds, we announced the appearance of the CaixaImpulse, an initiative of CaixaCapitalRisk for the creation of companies in the scientific field and yesterday, 15th September, the 15 projects selected in the first edition from among the 41 presented by different research centres, hospitals and universities were announced.
For the selection of the projects, which belong to various communities: Andalusia (1), Catalonia (11), Galicia (1) Madrid (1) and Navarre (1), priority was given to the transfer potential of the assets and their impact on society.
To guarantee the success of the projects, CaixImpulse offers financial support (€50,000), training tailored to their needs and a immersion in market reality which will allow them to test their asset value proposition, adapt it and thus maximise the likelihood of a successful transfer.
Among the projects that have been selected we find a project froml CIMA which focuses on The project will focus on the development of a new drug effective against haemorrhage and a project of the Institute for Bioengineering of Catalonia, which focuses on the treatment of chronic ulcers.
I2c Fund acquires Centauri Biotech
The Xunta de Galicia's venture capital company, Xesgalicia, has supported, through its I2C Fund, the biotech company Centauri Biotech, which develops veterinary pharmaceuticals.
I2C has acquired a 15% from the biotech company after underwriting a 50% of a capital increase 350,000 euros
Centauri Biotech, which they see as having great growth potential, is working on the development of drugs and treatments based on cell therapy and genetic diagnostics for inflammatory or degenerative joint-related lesions in animals. The company was founded in 2012 by four researchers.
"I was already involved in another biotech company, Health in Code , a technology-based company that aims to identify health problems through the use of genetic diagnostics" says Diego Gutierrez of Abra-Invest.
Sanifit closes a €36M round
a biopharmaceutical company dedicated to the development of a ,drug for the treatment of cardiovascular diseases related to calcification in dialysis-treated End Stage Renal Disease (ESRD) patients, has closed a €36.6m round led by Ysios Capital, with the participation of several international investors.
"This transaction is the largest round of financing for a Spanish company in the history of the biotech sector in Spain and one of the 10 largest in Europe so far this year," says Diego Gutierrez.
The capital increase will allow Sanifit to advance the clinical development of SNF472 to the end of phase IIb for the treatment of calcification-related cardiovascular diseases in patients with TRED and to phase II/III for the treatment of calciphylaxis.
If you are looking for financing, contact us. Abra-Invest has a team of experts in alternative financing at your disposal. Fill in the form or call us on +34 946024142
Other posts that may interest you